Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to 20 mg/kg) in six cohorts. Total AP inhibition was achieved through all cohorts and the ...
The MarketWatch News Department was not involved in the creation of this content. -- Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated ...
Results showed patients treated with ANX005 30mg/kg achieved a statistically significant 2.4-fold improvement on the GBS disability score at week 8 compared with placebo. Treatment with ANX005 was ...
Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
Cemdisiran, an investigational small interfering RNA (siRNA) therapy targeting complement component 5 (C5), met both its primary and a key secondary endpoint in the phase III NIMBLE trial of ...
These findings suggest complement protein levels may be an important biomarker for type 1 diabetes. Disruption of the complement system appears to precede the onset of islet autoimmunity (IA), making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results